BIO 2008: Germany on Cutting Edge in Biomanufacturing

San Diego (ots) - Germany is on the cutting edge in biotechnology
R&D and is a top player in large- and clinical-scale production.
Companies located in Germany are poised to profit from the latest
developments in biomanufacturing. These were the results of an expert
panel, at the BIO International Convention (BIO 2008) in San Diego,
California on June 18th. Invest in Germany co-chaired the panel along
with the CEO of a major transatlantic biotech consultancy.

Dr. Barbara Esch opened the discussion, entitled "Biomanufacturing
Solutions: Case Studies from Germany." She is responsible for the
business development of biopharmaceuticals in the Corporate Division
Biopharmaceuticals at the Boehringer Ingelheim GmbH in Ingelheim,
Germany. Her presentation provided an overview of the biotechnology
market in Germany, and offered examples of leading investment
successes in Germany. Dr. Wiltrud Treffenfeldt, Director of
Bioprocess Development, Dow AgroSciences LLC, discussed why the
German contract manufacturing industry is uniquely positioned to
create sustainable value in biopharmaceutical development and supply.
Dr. Uwe Marx, Chief Scientific Officer (CSO) of Probiogen, a
Berlin-based company that specializes in mammalian cell engineering
and cell culture, discussed clinical biomanufacturing and how it
serves the diverse needs of his company's client base.

Lastly Dr. Uwe Gottschalk, Vice President of Purification
Technologies at Sartorius AG, talked about his perception of the
current trends in biomanufacturing from the focus of an
internationally leading process technology provider.

Angelika Geiger, Director of Invest in Germany's San Francisco
office, and Steven Dickman, CEO of CBT Advisors chaired the panel.
CBT Advisors is an international strategic consultancy with a focus
on European and American biotech companies. Mr. Dickman also has
experience in Germany. He previously did biochemical research at the
German Cancer Research Center and served as correspondent for the
journal Nature in Germany.

Invest in Germany is the inward investment promotion agency of the
Federal Republic of Germany. It provides investors with comprehensive
support from site selection to the implementation of investment
decisions. Invest in Germany is at booth 711 throughout BIO 2008.

Originaltext: Invest in Germany
Digitale Pressemappe: http://www.presseportal.de/pm/55240
Pressemappe via RSS : http://www.presseportal.de/rss/pm_55240.rss2

Pressekontakt:
Eva Henkel
Invest in Germany
Phone: +49-30-200099-173
email: henkel@invest-in-germany.com
www.invest-in-germany.com